Posts From the monthly archives: "April 2013"

More from Bruce Booth with a realistic (and pessimistic) perspective on diagnostic investments and related challenges. Key question: “…how does one generate a return from early stage diagnostic investing – the translation of academia-derived insights into new clinically-validated diagnostic tests. Who is going to fund the next generation of new innovative Dx plays?” Unhealthy…(Read More)

On-Q-ity, a Cancer Diagnostic Company: R.I.P. | LifeSciVC. Lots of lessons from this story, but two of the key ones are: 1. Clinical trials are costly and risky. The company’s first investments were in 4 clinical trials for their most promising biomarkers, all of which failed. This effort consumed the better…(Read More)

Interesting opinion piece rebutting an open letter from Peter Meldrum, CEO of Myriad, in advance of the Supreme Court’s decision on the patentability of BRCA1/BRCA2. Myriad Genetics CEO Claims He Owns Your Genes – Forbes. Patents support the public good when the investments required to bring an advancement into the market are high enough…(Read More)

PageLines

Real-Time COVID R&D Tracking

As COVID-19 infections continue to spread, organizations with technologies or devices that can support new drug, vaccine, or test development have a life-saving contribution to make. The Amplion Intelligence Platform can alert you to new COVID-19 trial activities in real-time and automatically match you to partners who need your unique capabilities immediately. It’s already tomorrow somewhere, so let us help you start today.  Learn More

Request Access